Overview
Tirzepatide 20mg provides a larger quantity of the dual GLP-1/GIP receptor agonist in a single lyophilised vial, making it ideal for researchers conducting extended protocols or multi-sample studies. The compound targets both incretin receptors simultaneously, offering a distinct pharmacological profile compared to single-receptor agonists.
Nova Biolabs holds Tirzepatide 20mg in UK domestic stock, ensuring fast dispatch with no international shipping delays. Research-grade purity, verified by HPLC.
Key Research Areas
Extended Protocol Research
The 20mg vial is suited to researchers running longer experimental timelines or multiple parallel experiments requiring consistent compound batches.
Dose-Response Studies
Allows researchers to explore a wider concentration range within a single vial, supporting dose-response curve analysis in cellular models.
Receptor Co-Activation Studies
Tirzepatide's dual-receptor profile enables direct study of GLP-1 and GIP receptor co-activation and its downstream signalling effects.
Comparative Incretin Research
Frequently used alongside semaglutide in comparative studies examining the additional effect of GIP receptor engagement on metabolic signalling.
Product Specifications
| Format | Lyophilised powder |
| Quantity | 20mg per vial |
| Purity | >98% (HPLC verified) |
| Storage | Refrigerate at 2–8°C. Stable 24 months lyophilised. |
| Origin | UK domestic stock |
| Research use | In vitro / laboratory use only |